ADPT Adaptive Biotechnologies CorpcompanySEC Filings & Insider Trading Activity 2026
Latest Adaptive Biotechnologies Corp (ADPT) SEC EDGAR filings in 2026 — including the most recent 10-K annual report filed on February 26, 2026, a 10-Q quarterly report filed on November 5, 2025, an 8-K current report filed on February 5, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Adaptive Biotechnologies Corp (ADPT) (SEC CIK 1478320), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 10-K Annual Report AnalysisLatest 10-K (2025-12-31)
Business Overview
- • Core business model: Development and commercialization of immune medicine products using proprietary sequencing to decode adaptive immune system for diagnostics and therapeutics
- • New focus in 2024: Reorganization into MRD business specializing in clonoSEQ testing and Immune Medicine (IM) business emphasizing immune receptor sequencing and TCR-antigen mapping
Risk Factors
- • Regulatory risk: Potential non-coverage or inadequate reimbursement for clonoSEQ diagnostic tests by private and government payors affecting revenue
- • Geopolitical/macroeconomic risk: Dependence on Illumina as sole supplier for sequencers and reagents, risking operational disruption if supply is interrupted
Management Discussion & Analysis
- • Revenue $277.0M in 2025, up 55% YoY from $179.0M in 2024; MRD revenue $212.3M (+46%) and Immune Medicine $64.6M (+93%)
- • Operating margin negative: loss from operations $(57.1)M in 2025 vs $(162.5)M in 2024; Adjusted EBITDA positive $12.2M in 2025 vs loss $(80.4)M prior
AI 10-Q Quarterly Report AnalysisLatest 10-Q (2025-09-30)
Risk Factors
- • Newly added risk: Termination of Genentech Agreement in Aug 2025, with wind-down completing Feb 2026 may materially impact business and financial condition
- • Most materially updated risk: Loss of exclusive oncology collaboration may reduce Immune Medicine revenue to sequencing service fees only, lowering comparability to prior periods
Annual Reports Archive10-K
AI-powered analysis of Adaptive Biotechnologies Corp (ADPT) 10-K annual reports filed with SEC EDGAR.
Quarterly Reports Archive10-Q
AI-powered analysis of Adaptive Biotechnologies Corp (ADPT) 10-Q quarterly reports filed with SEC EDGAR.
Financial SummaryXBRL
| FY2022 | FY2023 | FY2024 | FY2025 | |
|---|---|---|---|---|
| Profitability | ||||
| Revenue | $185.3M | $170.3M | $179.0M | $277.0M |
| Operating Income | -$200.2M | -$227.0M | -$162.5M | -$57.1M |
| Net Income | -$200.2M | -$225.3M | -$159.5M | -$59.5M |
| Op. Margin | -108.0% | -133.3% | -90.8% | -20.6% |
| Net Margin | -108.0% | -132.3% | -89.1% | -21.5% |
| Balance Sheet | ||||
| Total Assets | $856.6M | $661.1M | $539.4M | $512.7M |
| Equity | $464.2M | $308.4M | $202.7M | $218.8M |
| ROE | -43.1% | -73.0% | -78.7% | -27.2% |
Source: XBRL financial data from Adaptive Biotechnologies Corp (ADPT) 10-K filings on SEC EDGAR. All figures in USD. Key metrics include revenue, net income, gross profit, gross profit margin, operating income, EPS (diluted), total assets, stockholders' equity, return on equity (ROE), operating cash flow, and capital expenditure.
Latest 2026 SEC Filings — 10-K, 10-Q, 8-K & Form 4
| Form | Filing Date | Period | Analysis | SEC |
|---|---|---|---|---|
10-K | Feb 26, 2026 | Dec 31, 2025 | Analysis | |
8-K | Feb 5, 2026 | — | — | |
8-K | Jan 12, 2026 | — | — | |
8-K | Dec 30, 2025 | — | — | |
10-Q | Nov 5, 2025 | Sep 30, 2025 | Analysis | |
10-Q | Aug 5, 2025 | Jun 30, 2025 | — | |
10-Q | May 1, 2025 | Mar 31, 2025 | — | |
10-K | Mar 3, 2025 | Dec 31, 2024 | — | |
10-Q | Nov 7, 2024 | Sep 30, 2024 | — | |
10-Q | Aug 1, 2024 | Jun 30, 2024 | — | |
10-Q | May 7, 2024 | Mar 31, 2024 | — | |
10-K | Feb 29, 2024 | Dec 31, 2023 | — | |
10-Q | Nov 9, 2023 | Sep 30, 2023 | — | |
10-Q | Aug 2, 2023 | Jun 30, 2023 | — | |
10-Q | May 3, 2023 | Mar 31, 2023 | — | |
10-K | Feb 14, 2023 | Dec 31, 2022 | — | |
10-Q | Nov 3, 2022 | Sep 30, 2022 | — | |
10-Q | Aug 3, 2022 | Jun 30, 2022 | — | |
10-Q | May 4, 2022 | Mar 31, 2022 | — | |
10-K | Feb 15, 2022 | Dec 31, 2021 | — | |
10-Q | Nov 3, 2021 | Sep 30, 2021 | — | |
10-Q | Aug 4, 2021 | Jun 30, 2021 | — | |
10-Q | May 5, 2021 | Mar 31, 2021 | — | |
10-K | Feb 24, 2021 | Dec 31, 2020 | — | |
10-Q | Nov 10, 2020 | Sep 30, 2020 | — |
Frequently Asked Questions
What are the latest ADPT SEC filings in 2026?
Adaptive Biotechnologies Corp (ADPT) has filed a 10-K annual report on February 26, 2026, a 10-Q quarterly report on November 5, 2025, an 8-K current report on February 5, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
When did ADPT file its most recent 10-K annual report?
Adaptive Biotechnologies Corp (ADPT) filed its most recent 10-K annual report on February 26, 2026. The 10-K includes audited financial statements, business overview, risk factors, and management discussion, all available on SignalX with AI-generated summaries and XBRL financial data.
How do I view ADPT 10-Q quarterly reports?
Adaptive Biotechnologies Corp (ADPT)'s most recent 10-Q quarterly report was filed on November 5, 2025. SignalX displays every ADPT 10-Q with AI-generated summaries of the MD&A (Management Discussion & Analysis) and Risk Factors sections, plus links to the original SEC EDGAR document.
What 8-K current reports has ADPT filed recently?
Adaptive Biotechnologies Corp (ADPT)'s most recent 8-K was filed on February 5, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find ADPT insider trading activity (Form 4)?
SignalX aggregates every ADPT Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does ADPT file with the SEC?
Adaptive Biotechnologies Corp (ADPT) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new ADPT filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Adaptive Biotechnologies Corp (ADPT).
What is ADPT's SEC CIK number?
Adaptive Biotechnologies Corp (ADPT)'s SEC CIK (Central Index Key) number is 1478320. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 1478320 to look up all ADPT filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find ADPT return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Adaptive Biotechnologies Corp (ADPT) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Adaptive Biotechnologies Corp SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 30+ filings.